Definitive Healthcare (NASDAQ:DH) Updates Q4 Earnings Guidance

by · The Cerbat Gem

Definitive Healthcare (NASDAQ:DH – Get Free Report) issued an update on its fourth quarter earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.07 for the period, compared to the consensus estimate of $0.06. The company issued revenue guidance of $60-$61 million, compared to the consensus revenue estimate of $60.33 million. Definitive Healthcare also updated its FY 2024 guidance to 0.340-0.350 EPS.

Definitive Healthcare Stock Up 0.2 %

DH traded up $0.01 during trading on Thursday, reaching $4.31. The stock had a trading volume of 543,715 shares, compared to its average volume of 748,693. Definitive Healthcare has a one year low of $3.19 and a one year high of $10.62. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.40 and a quick ratio of 2.40. The stock’s 50 day moving average is $4.38 and its two-hundred day moving average is $5.04.

Definitive Healthcare (NASDAQ:DH – Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.09 earnings per share for the quarter, meeting the consensus estimate of $0.09. The firm had revenue of $63.70 million during the quarter, compared to the consensus estimate of $63.19 million. Definitive Healthcare had a positive return on equity of 0.98% and a negative net margin of 156.65%. The company’s revenue was up 4.4% on a year-over-year basis. During the same period last year, the company earned $0.08 earnings per share. On average, analysts expect that Definitive Healthcare will post 0.07 EPS for the current fiscal year.

Analyst Ratings Changes

DH has been the subject of several research analyst reports. Robert W. Baird cut their price objective on Definitive Healthcare from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research note on Tuesday, August 6th. Stifel Nicolaus dropped their price objective on shares of Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating on the stock in a report on Wednesday, July 31st. JPMorgan Chase & Co. cut shares of Definitive Healthcare from a “neutral” rating to an “underweight” rating and reduced their target price for the company from $7.00 to $5.00 in a report on Wednesday, July 31st. Finally, Barclays dropped their price target on shares of Definitive Healthcare from $6.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $5.81.

Read Our Latest Analysis on Definitive Healthcare

About Definitive Healthcare

(Get Free Report)

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.

Featured Articles